KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opko Health (OPK) Raw Materials (2019 - 2025)

Opko Health's Raw Materials history spans 7 years, with the latest figure at $13.1 million for Q4 2025.

  • For Q4 2025, Raw Materials rose 38.99% year-over-year to $13.1 million; the TTM value through Dec 2025 reached $13.1 million, up 38.99%, while the annual FY2025 figure was $13.1 million, 38.99% up from the prior year.
  • Raw Materials reached $13.1 million in Q4 2025 per OPK's latest filing, up from $13.0 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $30.2 million in Q1 2023 to a low of $6.1 million in Q4 2021.
  • Average Raw Materials over 5 years is $14.3 million, with a median of $13.0 million recorded in 2025.
  • Peak YoY movement for Raw Materials: tumbled 92.96% in 2021, then skyrocketed 86.61% in 2024.
  • A 5-year view of Raw Materials shows it stood at $6.1 million in 2021, then grew by 10.78% to $6.8 million in 2022, then skyrocketed by 32.64% to $9.0 million in 2023, then grew by 4.87% to $9.4 million in 2024, then skyrocketed by 38.99% to $13.1 million in 2025.
  • Per Business Quant, the three most recent readings for OPK's Raw Materials are $13.1 million (Q4 2025), $13.0 million (Q3 2025), and $14.3 million (Q2 2025).